Spotlight on SynaptixBio – A Virtual Approach to Developing an Oligonucleotide Therapy for a CNS Disorder
Time: 2:30 pm
day: Day One
Details:
- TUBB4A Leukodystrophy and it’s suitability for an oligonucleotide therapeutic approach
- SynaptixBio’s virtual strategy to outsourcing and developing a therapeutic
- Exploring the pros and cons of applying a virtual model to development – learnings from a start-up biotechnology company
